FY2024 EPS Estimates for Amedisys, Inc. (NASDAQ:AMED) Raised by Analyst

Amedisys, Inc. (NASDAQ:AMED) – Research analysts at William Blair increased their FY2024 earnings per share (EPS) estimates for Amedisys in a report released on Thursday, April 25th. William Blair analyst M. Larew now forecasts that the health services provider will post earnings per share of $4.54 for the year, up from their prior estimate of $4.37. The consensus estimate for Amedisys’ current full-year earnings is $4.58 per share.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $571.41 million for the quarter, compared to analysts’ expectations of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.00 EPS.

Several other analysts have also recently weighed in on AMED. Raymond James restated a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. StockNews.com downgraded Amedisys from a “buy” rating to a “hold” rating in a research report on Friday, April 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research note on Thursday, April 25th. Finally, Royal Bank of Canada increased their price objective on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 25th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Amedisys currently has a consensus rating of “Hold” and an average target price of $97.50.

Amedisys Trading Up 0.2 %

Shares of Amedisys stock opened at $92.05 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.09 and a quick ratio of 1.09. Amedisys has a 1 year low of $73.10 and a 1 year high of $96.44. The firm has a market cap of $3.01 billion, a PE ratio of -143.83, a PEG ratio of 3.41 and a beta of 0.86. The company has a 50 day simple moving average of $92.51 and a two-hundred day simple moving average of $93.35.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AMED. Banque Cantonale Vaudoise bought a new position in Amedisys during the 1st quarter worth approximately $60,000. Cetera Trust Company N.A purchased a new stake in shares of Amedisys during the fourth quarter valued at approximately $215,000. CWM LLC grew its holdings in shares of Amedisys by 40.4% in the fourth quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock worth $250,000 after purchasing an additional 757 shares during the last quarter. Contravisory Investment Management Inc. purchased a new position in shares of Amedisys in the fourth quarter worth $258,000. Finally, Mesirow Institutional Investment Management Inc. increased its stake in shares of Amedisys by 9.9% in the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock worth $270,000 after buying an additional 257 shares during the period. 94.36% of the stock is owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.